Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The company has been focusing on cutting down working capital and reducing borrowings by about ₹100 crores recently, indicating prudent financial management. There is a mention of a proposal to invest around ₹150 crores in the Sotanala project starting next calendar year, but the source of funding is not specified. The management did not discuss any share buyback plans but welcomed suggestions for it. Overall, no definitive announcement or indication of imminent debt or equity

Any current/future capex/capital investment/strategic investment?

In the last 3-4 years, Insecticides India Limited has invested roughly ₹300 crore in the Dahej and Chopanki plants. There is a planned investment of approximately ₹150 crore in the Sotanala project expected to start in the next calendar year. A new building project at the Dahej site is awaiting final approval, with a target to start early December 2023. Focus on capacity expansion through these new plants (Dahej, Chopanki, Sotanala) to support future growth. Emphasis on new-generation technicals and sustainable formulations (water-based, WDE, WP) as part of capital deployment. Investments are

Future growth expectations in sales/revenue/volumes?

The company aims to sustain around 20% CAGR growth in the next two years (FY25 and FY26), similar to the current pace. Margin improvements are expected alongside revenue growth driven by a better product mix, especially with higher-margin Maharatna and specialty products. Newly launched products, many yet to have a full market season, have received strong market response and are expected to contribute significantly in coming years. The export segment is anticipated to grow well due to China Plus One and Europe Plus One trends, with a revised export target of ₹150 crore for this year like

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects continuous growth with a CAGR mission; grew ~20% in the past year and maintaining similar pace currently (Page 18). New product launches are driving growth; several products exceeding ₹50 crore in sales, with some crossing ₹100 crore (Page 17). Margins are expected to improve gradually through product mix improvements and focusing on high-margin specialty (Maharatna) products (Page 18). Gross margins likely to improve owing to stabilization of raw material prices and shift towards value-added products; technicals forecasted to generate 5x fixed asset returns (Pages 17

Current/ Expected Orderbook/ Pending Orders?

There is no explicit mention of the current or expected order book or pending orders in the provided transcript on page 18 or surrounding pages. Rajesh Aggarwal discusses continuous growth in products and market appreciation but does not specify order book details. He mentions ongoing discussions and opportunities in contract manufacturing and CDMO but no concrete order confirmations. The company emphasizes new product launches and strong market response but no quantitative data on orders is provided. Overall focus appears on sales growth, product pipeline, and market strategy rather than disc

IN US

Sale is live|00:00:00left today

Insecticides India LtdQ3 FY23Fertilizers & Agrochemicals

Insecticides India Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹669P/E: 14.8Market Cap: ₹2.1K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→The company aims to sustain around 20% CAGR growth in the next two years (FY25 and FY26), similar to the current pace.
→Margin improvements are expected alongside revenue growth driven by a better product mix, especially with higher-margin Maharatna and specialty products.
→Newly launched products, many yet to have a full market season, have received strong market response and are expected to contribute significantly in coming years.
→The export segment is anticipated to grow well due to China Plus One and Europe Plus One trends, with a revised export target of ₹150 crore for this year likely to be met.
→New plants at Dahej and Chopanki and backward integration for technicals will support capacity and value growth.
→Product innovation, branding, and increased penetration (sales team >700, distributors >8000) further underpin volume and sales growth.
→Focus on sustainable water-based formulations and patenting new formulations will also drive future growth.

Margin guidance

Category 3

→The company expects continuous growth with a CAGR mission; grew ~20% in the past year and maintaining similar pace currently (Page 18).
→New product launches are driving growth; several products exceeding ₹50 crore in sales, with some crossing ₹100 crore (Page 17).
→Margins are expected to improve gradually through product mix improvements and focusing on high-margin specialty (Maharatna) products (Page 18).
→Gross margins likely to improve owing to stabilization of raw material prices and shift towards value-added products; technicals forecasted to generate 5x fixed asset returns (Pages 17, 16).
→The company aims to beat industry growth consistently, targeting ~20% top-line growth for next two years with bottom-line improvements (Page 17).
→Focus on new plants and products, increasing B2B and exports presence, and cutting costs supports margin expansion and earnings growth (Pages 16, 8).
→Management cautious on exact margin/earnings guidance but confident in sustainable growth and improving profitability (Pages 18, 13).

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company has been focusing on cutting down working capital and reducing borrowings by about ₹100 crores recently, indicating prudent financial management.
→There is a mention of a proposal to invest around ₹150 crores in the Sotanala project starting next calendar year, but the source of funding is not specified.
→The management did not discuss any share buyback plans but welcomed suggestions for it.
→Overall, no definitive announcement or indication of imminent debt or equity fundraising was made during the call.

Order book

→There is no explicit mention of the current or expected order book or pending orders in the provided transcript on page 18 or surrounding pages.
→Rajesh Aggarwal discusses continuous growth in products and market appreciation but does not specify order book details.
→He mentions ongoing discussions and opportunities in contract manufacturing and CDMO but no concrete order confirmations.
→The company emphasizes new product launches and strong market response but no quantitative data on orders is provided.
→Overall focus appears on sales growth, product pipeline, and market strategy rather than disclosing order book status.

Capex plans

Yes

→In the last 3-4 years, Insecticides India Limited has invested roughly ₹300 crore in the Dahej and Chopanki plants.
→There is a planned investment of approximately ₹150 crore in the Sotanala project expected to start in the next calendar year.
→A new building project at the Dahej site is awaiting final approval, with a target to start early December 2023.
→Focus on capacity expansion through these new plants (Dahej, Chopanki, Sotanala) to support future growth.
→Emphasis on new-generation technicals and sustainable formulations (water-based, WDE, WP) as part of capital deployment.
→Investments are aligned to improve product mix with value-added and patented products, helping sustain higher margins and market edge.

How does Insecticides India Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Insecticides India Ltd

Rev 2Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Insecticides India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio